Lexicon Pharmaceuticals (NASDAQ: LXRX) has recently received a number of price target changes and ratings updates:

  • 9/20/2016 – Lexicon Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
  • 9/12/2016 – Lexicon Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $21.00 to $25.00. They now have a “buy” rating on the stock.
  • 9/12/2016 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $21.00 price target on the stock.
  • 9/11/2016 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
  • 9/9/2016 – Lexicon Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company.
  • 8/11/2016 – Lexicon Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
  • 8/11/2016 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC.
  • 8/5/2016 – Lexicon Pharmaceuticals had its price target raised by analysts at Wedbush from $30.00 to $31.00. They now have an “outperform” rating on the stock.
  • 8/5/2016 – Lexicon Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $25.00 to $26.00. They now have a “buy” rating on the stock.
  • 8/3/2016 – Lexicon Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
  • 8/2/2016 – Lexicon Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $21.00 price target on the stock.

Shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) traded down 0.42% on Thursday, hitting $18.82. 643,640 shares of the stock traded hands. The stock has a 50 day moving average of $16.15 and a 200-day moving average of $14.23. Lexicon Pharmaceuticals Inc. has a 1-year low of $7.65 and a 1-year high of $19.62. The stock’s market cap is $1.95 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04. The company earned $20.10 million during the quarter, compared to analysts’ expectations of $12.36 million. Lexicon Pharmaceuticals had a negative net margin of 13.42% and a negative return on equity of 9.03%. Lexicon Pharmaceuticals’s quarterly revenue was up 5186.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.27) earnings per share. On average, equities research analysts expect that Lexicon Pharmaceuticals Inc. will post ($1.54) EPS for the current year.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

5 Day Chart for NASDAQ:LXRX

Receive News & Ratings for Lexicon Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.